Screening and verification of antiviral compounds against HSV-1 using a method based on a plaque inhibition assay
Abstract Background Herpes simplex virus type 1 (HSV-1) infection is a common viral disease that mainly causes oral lesions, but can also cause genital lesions in some instances. Current treatments with nucleoside analogs are limited by the emergence of drug resistance. Therefore, novel anti-HSV-1 d...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-023-08843-3 |
| _version_ | 1797377094997508096 |
|---|---|
| author | Yingxian Yin Jiahui Li Ling Su Zhiying Ou Qingqun Lv Misi Xiao Changbing Wang Dan Zeng Yiling Gu Fengxia Yang Minxia Chen Shaojuan Feng Wanming Hu Fengling Bu Bing Zhu Yi Xu |
| author_facet | Yingxian Yin Jiahui Li Ling Su Zhiying Ou Qingqun Lv Misi Xiao Changbing Wang Dan Zeng Yiling Gu Fengxia Yang Minxia Chen Shaojuan Feng Wanming Hu Fengling Bu Bing Zhu Yi Xu |
| author_sort | Yingxian Yin |
| collection | DOAJ |
| description | Abstract Background Herpes simplex virus type 1 (HSV-1) infection is a common viral disease that mainly causes oral lesions, but can also cause genital lesions in some instances. Current treatments with nucleoside analogs are limited by the emergence of drug resistance. Therefore, novel anti-HSV-1 drugs are urgently needed. Methods In this study, we screened a library of 2080 compounds for anti-HSV-1 activity using a plaque formation assay. We selected 11 potential inhibitors of HSV-1 and further evaluated their antiviral effects by plaque reduction assay and real-time polymerase chain reaction (qPCR). Results Five compounds, namely ginsenoside Rd, brassinolide, rosamultin, 3’-hydroxy puerarin, and clinafloxacin HCl, showed potent anti-HSV-1 activity and completely suppressed plaque formation at a concentration of 10 µM. Among them, clinafloxacin HCl, a fluoroquinolone antibiotic, exhibited a high selectivity index for HSV-1. Conclusions Our findings suggest that these five compounds have potential antiviral properties against HSV-1 and may have different mechanisms of action. Further studies are warranted to elucidate the antiviral mechanisms of these compounds and to explore their therapeutic potential for HSV-1 infection. |
| first_indexed | 2024-03-08T19:49:02Z |
| format | Article |
| id | doaj.art-137b60fd72904b4bb89a3dbe1e855a69 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-03-08T19:49:02Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-137b60fd72904b4bb89a3dbe1e855a692023-12-24T12:10:40ZengBMCBMC Infectious Diseases1471-23342023-12-0123111010.1186/s12879-023-08843-3Screening and verification of antiviral compounds against HSV-1 using a method based on a plaque inhibition assayYingxian Yin0Jiahui Li1Ling Su2Zhiying Ou3Qingqun Lv4Misi Xiao5Changbing Wang6Dan Zeng7Yiling Gu8Fengxia Yang9Minxia Chen10Shaojuan Feng11Wanming Hu12Fengling Bu13Bing Zhu14Yi Xu15Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Infectious Diseases, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Genetics and Endocrinology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityGuangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversitySchool of Pediatrics, Guangzhou Medical UniversityCentral Laboratory, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityCentral Laboratory, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Infectious Diseases, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Infectious Diseases, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Infectious Diseases, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Infectious Diseases, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Oral and Maxillofacial Surgery, Women and Children’s Medical Center, Guangzhou Medical UniversityGuangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Disease Control and Prevention, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityCentral Laboratory, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityDepartment of Infectious Diseases, Guangzhou Women and Children’s Medical Center, Guangzhou Medical UniversityAbstract Background Herpes simplex virus type 1 (HSV-1) infection is a common viral disease that mainly causes oral lesions, but can also cause genital lesions in some instances. Current treatments with nucleoside analogs are limited by the emergence of drug resistance. Therefore, novel anti-HSV-1 drugs are urgently needed. Methods In this study, we screened a library of 2080 compounds for anti-HSV-1 activity using a plaque formation assay. We selected 11 potential inhibitors of HSV-1 and further evaluated their antiviral effects by plaque reduction assay and real-time polymerase chain reaction (qPCR). Results Five compounds, namely ginsenoside Rd, brassinolide, rosamultin, 3’-hydroxy puerarin, and clinafloxacin HCl, showed potent anti-HSV-1 activity and completely suppressed plaque formation at a concentration of 10 µM. Among them, clinafloxacin HCl, a fluoroquinolone antibiotic, exhibited a high selectivity index for HSV-1. Conclusions Our findings suggest that these five compounds have potential antiviral properties against HSV-1 and may have different mechanisms of action. Further studies are warranted to elucidate the antiviral mechanisms of these compounds and to explore their therapeutic potential for HSV-1 infection.https://doi.org/10.1186/s12879-023-08843-3Antiviral drug screeningHSV-1Plaque formationPlaque inhibition test |
| spellingShingle | Yingxian Yin Jiahui Li Ling Su Zhiying Ou Qingqun Lv Misi Xiao Changbing Wang Dan Zeng Yiling Gu Fengxia Yang Minxia Chen Shaojuan Feng Wanming Hu Fengling Bu Bing Zhu Yi Xu Screening and verification of antiviral compounds against HSV-1 using a method based on a plaque inhibition assay BMC Infectious Diseases Antiviral drug screening HSV-1 Plaque formation Plaque inhibition test |
| title | Screening and verification of antiviral compounds against HSV-1 using a method based on a plaque inhibition assay |
| title_full | Screening and verification of antiviral compounds against HSV-1 using a method based on a plaque inhibition assay |
| title_fullStr | Screening and verification of antiviral compounds against HSV-1 using a method based on a plaque inhibition assay |
| title_full_unstemmed | Screening and verification of antiviral compounds against HSV-1 using a method based on a plaque inhibition assay |
| title_short | Screening and verification of antiviral compounds against HSV-1 using a method based on a plaque inhibition assay |
| title_sort | screening and verification of antiviral compounds against hsv 1 using a method based on a plaque inhibition assay |
| topic | Antiviral drug screening HSV-1 Plaque formation Plaque inhibition test |
| url | https://doi.org/10.1186/s12879-023-08843-3 |
| work_keys_str_mv | AT yingxianyin screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT jiahuili screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT lingsu screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT zhiyingou screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT qingqunlv screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT misixiao screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT changbingwang screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT danzeng screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT yilinggu screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT fengxiayang screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT minxiachen screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT shaojuanfeng screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT wanminghu screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT fenglingbu screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT bingzhu screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay AT yixu screeningandverificationofantiviralcompoundsagainsthsv1usingamethodbasedonaplaqueinhibitionassay |